REG - Ondine Biomedical - Marked Reduction in SSIs at Ottawa Heart Institute

Ondine BiomedicalAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260423:nRSW5660Ba&default-theme=true

RNS Number : 5660B  Ondine Biomedical Inc.  23 April 2026

23 April 2026

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

University of Ottawa Heart Institute Reduces Surgical Site Infections
Following Implementation of Steriwave Nasal Photodisinfection

Ondine Biomedical Inc. (AIM: OBI), a global leader in light-activated
antimicrobial therapies, announces that the University of Ottawa Heart
Institute ("UOHI"), Canada's largest and foremost academic health sciences
centre dedicated to cardiovascular care, found notable results in patient
safety following the integration of Steriwave(®) nasal decolonisation into
its presurgical protocols.

In a clinical evaluation at UOHI, outcomes from a 24-month control period
using mupirocin were compared with an 8-month pilot programme incorporating
Steriwave. Consistent with results reported from other hospitals, the addition
of Steriwave was associated with a statistically significant reduction in
Surgical Site Infection ("SSI") rates among cardiac surgery patients. This
marked decline has significantly impacted the Institute's infection rates,
improving postoperative recovery and patient outcomes.

These findings have been submitted to an upcoming major international cardiac
conference, and a detailed manuscript describing the study's methodology and
comprehensive results is currently in development for submission to a
peer-reviewed medical journal.

Dr. Fraser Rubens, MD, MSc, FACS, FRCSC, Professor of Cardiac Surgery at the
University of Ottawa, noted:

"Achieving a marked reduction in SSIs is a monumental shift that not only
saves lives but also reduces the significant strain that surgical
complications place on the healthcare system. In the ongoing race against
antibiotic resistance, photodisinfection therapy provides an innovative and
promising strategy for enhancing patient safety."

Carolyn Cross, CEO of Ondine Biomedical, stated:

"Surgical site infections represent one of the most costly and dangerous
complications in cardiac surgery, often leading to extended hospital stays,
readmissions, and increased mortality. By implementing a non-antibiotic, rapid
decolonisation solution, UOHI continues to lead the way in both clinical
innovation and antimicrobial stewardship. We are pleased to support UOHI's
efforts to protect their cardiac patients from the rise in multidrug
resistance."

Nasal decolonisation is a critical step in preventing healthcare-associated
infections, as the nose is a primary reservoir for pathogens like
Staphylococcus aureus. Unlike traditional antibiotic ointments, which can be
limited by patient compliance and rising antimicrobial resistance, Steriwave
uses photodynamic disinfection to rapidly eliminate bacteria, viruses, and
fungi without the risk of generating "superbugs".

 

Enquiries:

 

 Ondine Biomedical Inc.                                     www.ondinebio.com
 Carolyn Cross, CEO                                         +1 604 669 0555

or via 5654 & Company

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                              +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Adviser)
 James Steel, Dr. Chris Golden                              +44 (0)20 7418 8900

 5654 & Company (Financial PR and IR Adviser)               ondinebiomedical@5654.co.uk
 Matthew Neal, Chris Gardner, Melissa Gardiner              +44 0791 7800 011

                                                            +44 0775 7697 357

 

About the University of Ottawa Heart Institute

Recognized as one of Canada's most distinguished heart health centres, the
Ottawa Heart Institute delivers unparalleled patient care, leads globally
recognized research from bench to bedside, and plays a national leadership
role in heart disease prevention. Serving communities from Eastern Ontario,
Western Quebec, Nunavut and Newfoundland and Labrador, the Institute strives
to ensure care, research and education support heart health for all. The
Ottawa Heart Institute promise remains: Always putting patients first. For
more information, visit www.ottawaheart.ca (http://www.ottawaheart.ca/) .

About Steriwave(®) and its Mode of Action

Steriwave nasal photodisinfection is a non-invasive and painless treatment
that uses a proprietary light-activated photosensitive agent to destroy
harmful bacteria, viruses, and fungi, including antibiotic-resistant strains,
in the nasal passages. The procedure takes five minutes and, unlike
antibiotics, is effective immediately and allows the normal nasal microbiome
to recover quickly, without fostering antimicrobial resistance.

The two-step process involves applying the Steriwave formulation in the
nostrils where it electrostatically binds to microbes rather than human cells.
The area is then illuminated with safe red light to activate the formulation,
triggering an oxidative burst that physically destroys all manner of pathogens
within minutes. This rapid and overwhelming oxidative stress makes it
extremely difficult for pathogens to develop resistance, and the process stops
immediately once the light is turned off. Steriwave has been used in a growing
number of hospitals since 2011.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system is CE-marked in Europe and is approved
for nasal decolonisation in Canada, Australia, Mexico, and several other
countries under the name Steriwave®. In the US, it has been granted Qualified
Infectious Disease Product designation and Fast Track status by the FDA and is
currently undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical indications
such as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGZDMZVGVZZ



            Copyright 2019 Regulatory News Service, all rights reserved